Impact of <em>SLC22A1</em> variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitus

Ortega‑Ayala,Adiel; De Andrés,Fernando; Llerena,Adrián; Bartolo‑Montiel,Carlos M.; Molina‑Guarneros,Juan Arcadio

doi:10.3892/br.2024.1806

Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitus

Authors:
- Adiel Ortega‑Ayala
- Fernando De Andrés
- Adrián Llerena
- Carlos M. Bartolo‑Montiel
- Juan Arcadio Molina‑Guarneros
View Affiliations

Affiliations: Department of Pharmacology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico, Department of Analytical Chemistry and Food Technology, Faculty of Pharmacy, University of Castilla‑La Mancha, 02071 Albacete, Spain, University Institute for Bio‑sanitary Research of Extremadura, 06002 Badajoz, Spain, Directorate of Planification, Teaching, and Research, High‑Speciality Regional Hospital of Ixtapaluca, Ixtapaluca 56530, Mexico
Published online on: June 17, 2024 https://doi.org/10.3892/br.2024.1806
Article Number: 117
Copyright: © Ortega‑Ayala et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Type 2 diabetes mellitus (T2DM) is a major global health problem. Response to first‑line therapy is variable. This is partially due to interindividual variability across those genes codifying transport, metabolising, and drug activation proteins involved in first‑line pharmacological treatment. Single nucleotide polymorphisms (SNPs) of genes SLC22A1, SLC22A2 and SLC22A3 affect metformin therapeutic response in patients with T2DM patients. The present study investigated allelic and genotypic frequencies of organic cation (OCT)1, OCT2, and OCT3 polymorphisms among metformin‑treated patients with type 2 diabetes mellitus (T2DM). It also reports the association between clinical and genetic variables with glycated haemoglobin (HbA1c) control in 59 patients with T2DM. Patients were genotyped through real‑time PCR (TaqMan assays). Metformin plasmatic levels were determined by mass spectrometry. Neither the analysis of HbA1c control by SNPs in SLC22A1, SLC22A2 and SLC22A3, nor the dominant genotypic model analysis yielded statistical significance between genotypes in polymorphisms rs72552763 (P=0.467), rs622342 (P=0.221), rs316019 (P=0.220) and rs2076828 (P=0.215). HbA1c levels were different in rs72552763 [GAT/GAT, 6.0 (5.7‑6.6), GAT/del=6.5 (6.2‑9.0), del/del=6.5 (6.4‑6.8); P=0.022] and rs622342 [A/A=6.0 (5.8‑6.5), A/C=6.4 (6.1‑7.7), C/C=6.8 (6.4‑9.3); P=0.009] genotypes. The dominant genotypic model found the lowest HbA1c levels in GAT/GAT (P=0.005) and A/A (P=0.010), in rs72552763 (GAT/GAT vs. GAT/del + del/del) and rs622342 (A/A vs. A/C + CC), respectively. There was a significant correlation between HbA1c levels and metformin dosage amongst del allele carriers in rs72552763 (β₁=0.14, P<0.001, r²=0.387), as opposed to GAT/GAT in rs72552763. There were no differences between HbA1c values in the test set and those predicted by machine learning models employing a simple linear regression based on metformin dosage. Therefore, rs72552763 and rs622342 polymorphisms in SLC22A1 may affect metformin response determined by HbA1c levels in patients with T2DM. The del allele of SNP rs72552763 may serve as a metformin response biomarker.

View Figures

View References

1	Standl E, Khunti K, Hansen TB and Schnell O: The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol. 26 (2_suppl):S7–S14. 2019.PubMed/NCBI View Article : Google Scholar
2	Sun H, Pouya P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et al: IDF DiabetesAtlas:Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 183(109119)2022.PubMed/NCBI View Article : Google Scholar
3	Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero A, Gaona-Pineda EB, Lazcano-Ponce E, Martínez-Barnetche J, Alpuche-Aranda C, Rivera-Dommarco J and Shamah-Levy T: Metodología de la Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19. Salud Publica Mex. 63:444–451. 2021.PubMed/NCBI View Article : Google Scholar : (In Spanish).
4	Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352:837–853. 1998.PubMed/NCBI
5	American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2022. Diabetes Care. 45 (Suppl 1):S1–S2. 2022.PubMed/NCBI View Article : Google Scholar
6	LaMoia TE and Shulman GI: Cellular and molecular mechanisms of metformin action. Endocr Rev. 42:77–96. 2021.PubMed/NCBI View Article : Google Scholar
7	Staiger H, Schaeffeler E, Schwab M and Häring HU: Pharmacogenetics: Implications for modern type 2 diabetes therapy. Rev Diabet Stud. 12:363–376. 2015.PubMed/NCBI View Article : Google Scholar
8	Huang C and Florez JC: Pharmacogenetics in type 2 diabetes: Potential implications for clinical practice. Genome Med. 3(76)2011.PubMed/NCBI View Article : Google Scholar
9	Weizzman Institute of Science: Gene cards SLC22A1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC22A1. Accessed July 20, 2023.
10	Koepsell H, Lips K and Volk C: Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 24:1227–1251. 2007.PubMed/NCBI View Article : Google Scholar
11	Lai Y: Organic anion, organic cation and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs, OCTs, OCTNs and MATEs). In: Transporters in Drug Discovery and Development. Woodhead Publishing, Sawston, 2013.
12	Goswami S, Gong L, Giacomini K, Altman RB and Klein TE: PharmGKB summary: Very important pharmacogene information for SLC22A1. Pharmacogenet Genomics. 24:324–328. 2014.PubMed/NCBI View Article : Google Scholar
13	Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG and Stricker BH: Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 20:38–44. 2010.PubMed/NCBI View Article : Google Scholar
14	World Health Organization (WHO): Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. WHO, Geneva, 2006. https://iris.who.int/handle/10665/43588. Accessed April 08, 2024).
15	Ortega-Ayala A, Rodríguez-Rivera NS, Andrés F, Llerena A, Pérez-Silva E, Espinosa-Sánchez AG and Molina-Guarneros JA: Pharmacogenetics of metformin transporters suggests no association with therapeutic inefficacy among diabetes type 2 mexican patients. Pharmaceuticals (Basel). 15(774)2022.PubMed/NCBI View Article : Google Scholar
16	Health Secretary: Official Mexican Normative NOM-177-SSA1-2013 [Internet]. DOF2013. http://www.dof.gob.mx/nota_detalle.php?codigo=5314833&fecha=20/09/2013. Accessed September 17, 2023.
17	US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM): Bioanalytical Methods Validation, Guidance for lndustry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed May 24, 2018.
18	Shamah Levy T, Cuevas Nasu L, Morales Ruan MC, Mundo Rosas V, Méndez Gómez-Humarán I and Villalpando Hernández S: Profile of the health and nutritional status of older adults in Mexico. 2012 National Health and Nutrition Survey. J Frailty Aging. 2:184–191. 2013.PubMed/NCBI View Article : Google Scholar
19	World Health Organization (WHO): Physical Status: The Use of and Interpretation of Anthropometry, Report of a WHO Expert Committee. WHO, Geneva, 1995. https://apps.who.int/iris/handle/10665/37003. Accessed July 21, 2023.
20	Reséndiz-Abarca CA, Flores-Alfaro E, Suárez-Sánchez F, Cruz M, Valladares-Salgado A, Del Carmen Alarcón-Romero L, Wacher-Rodarte NA and Gómez-Zamudio JH: Altered glycemic control associated with polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican population with type 2 diabetes mellitus treated with metformin: A cohort study. J Clin Pharmacol. 59:1384–1390. 2019.PubMed/NCBI View Article : Google Scholar
21	Menjivar M, Sánchez-Pozos K, Jaimes-Santoyo J, Monroy-Escutia J, Rivera-Santiago C, de Los Ángeles Granados-Silvestre M and Ortiz-López MG: Pharmacogenetic evaluation of metformin and sulphonylurea response in mexican mestizos with type 2 diabetes. Curr Drug Metab. 21:291–300. 2020.PubMed/NCBI View Article : Google Scholar
22	Christensen MH, Brasch-Andersenb C, Greene H, Nielsen F, Damkierc P, Beck-Nielsen H and Brosena K: The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 21:837–850. 2011.PubMed/NCBI View Article : Google Scholar
23	Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN and Pearson ER: Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study. Diabetes. 58:1434–1439. 2009.PubMed/NCBI View Article : Google Scholar
24	Umamaheswaran G, Praveen RG, Damodaran SE, Das AK and Adithan C: Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 15:511–517. 2015.PubMed/NCBI View Article : Google Scholar
25	Dujic T, Causevic A, Bego T, Malenica M, Velija-Asimi Z, Pearson ER and Semiz S: Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with type 2 diabetes. Diabet Med. 33:511–514. 2016.PubMed/NCBI View Article : Google Scholar
26	Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et al: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 117:1422–1431. 2007.PubMed/NCBI View Article : Google Scholar